| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/10/2007 | WO2007052937A2 Dosing regimens for cox-2 inhibitor |
| 05/10/2007 | WO2007052850A1 USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
| 05/10/2007 | WO2007052849A1 USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
| 05/10/2007 | WO2007052843A1 Heterocyclic amide compound and use thereof |
| 05/10/2007 | WO2007052837A1 Gastrointestinal function promoter |
| 05/10/2007 | WO2007052831A1 Preventives/remedies for urinary disturbance |
| 05/10/2007 | WO2007052808A1 Hydrazide compound and thrombopoietin receptor activator |
| 05/10/2007 | WO2007052802A1 Reduced coenzyme q10-containing composition which is stable against oxidation, and method for stabilization of reduced coenzyme q10 |
| 05/10/2007 | WO2007052794A1 o-SUBSTITUTED ANILINE DERIVATIVE AND ANTIOXIDANT DRUG |
| 05/10/2007 | WO2007052793A1 Patch |
| 05/10/2007 | WO2007052740A1 Equol level regulator |
| 05/10/2007 | WO2007052738A1 Medicinal composition showing improved drug absorbability |
| 05/10/2007 | WO2007052629A1 Oligo double-stranded rna and pharmaceutical composition |
| 05/10/2007 | WO2007052615A1 Pyridine derivative substituted by heterocycle and fungicide containing the same |
| 05/10/2007 | WO2007052592A1 Pharmaceutical preparation having excellent photostability |
| 05/10/2007 | WO2007052541A1 Prodrug of donepezil hydrochloride |
| 05/10/2007 | WO2007052398A1 Method of screening compound useful in treating allergic disease |
| 05/10/2007 | WO2007052357A1 Isosorbide preparation |
| 05/10/2007 | WO2007052330A1 Reduced chalcone compound and method of producing the same, reduced product of fat-soluble licorice root extract and method of producing the same, cyclooxygenase-2 activity inhibitor, whitening agent, antiinflammatory agent and cosmetic |
| 05/10/2007 | WO2007052309A2 Improved process for manufacturing statins |
| 05/10/2007 | WO2007052307A2 Stable solid oral dosage forms of valsartan |
| 05/10/2007 | WO2007052167A2 Stable composition for a pharmaceutical formulation containing olanzapine |
| 05/10/2007 | WO2007052164A2 A pharmaceutical formulation containing olanzapine |
| 05/10/2007 | WO2007052134A1 (2s)-2-aminomethyl-5-ethyl heptanoic acid its pharmaceutical use |
| 05/10/2007 | WO2007052124A1 Tetrahydronaphthyridine derivative |
| 05/10/2007 | WO2007052123A2 Pyrazine derivatives as sodium channel modulators for the treatment of pain |
| 05/10/2007 | WO2007052076A2 Formulations comprising jorumycin-, reni eramycin-, safracin- or saframycin-related compounds for treating proliferative diseases |
| 05/10/2007 | WO2007052042A2 A hollow fibre-based biocompatible drug delivery device with one or more layers |
| 05/10/2007 | WO2007052013A1 A combination of cannabinoids for the treatment of peripheral neurophatic pain |
| 05/10/2007 | WO2007052000A1 Pyrazoles useful in the treatment of inflammation |
| 05/10/2007 | WO2007051982A1 Triazole compounds as lipoxygenase inhibitors |
| 05/10/2007 | WO2007051981A1 Pyrazoles useful in the treatment of inflammation |
| 05/10/2007 | WO2007051920A1 Methanone compounds and the use thereof in pharmaceutical compositions, in particular for treating cardiovascular diseases |
| 05/10/2007 | WO2007051877A1 Solid oral forms of ebastine |
| 05/10/2007 | WO2007051862A1 Combination of organic compounds |
| 05/10/2007 | WO2007051847A1 Tricyclo substituted amides as glucokinase modulators |
| 05/10/2007 | WO2007051846A1 Tricyclo substituted amides |
| 05/10/2007 | WO2007051845A1 Tricyclo substituted amides |
| 05/10/2007 | WO2007051836A2 Compositions for treating dermatological and neurological disorders |
| 05/10/2007 | WO2007051829A1 Oleuropein for the treatment of conditions associated to the peripheral vascular disease |
| 05/10/2007 | WO2007051735A1 Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors |
| 05/10/2007 | WO2007051641A1 Use of calcitonin for the treatment of ra |
| 05/10/2007 | WO2007051630A1 Heterocyclic compounds and their use as antifouling agents |
| 05/10/2007 | WO2007051622A1 Lead structures for cytostatic compounds based on spiro compounds |
| 05/10/2007 | WO2007051596A1 Novel retinyl biotinates and use thereof |
| 05/10/2007 | WO2007051594A1 Treatment of diabetes |
| 05/10/2007 | WO2007051586A1 Bacteriostatic and/or bactericide agent for cosmetic and/or dermopharmaceutical preparations and preparations containing this agent |
| 05/10/2007 | WO2007051532A1 Phenylenebisoxazolidine derivatives and their use as anticoagulants |
| 05/10/2007 | WO2007051475A1 A concentrate derived from a milk product enriched in naturally occurring sialyllactose and a process for preparation thereof |
| 05/10/2007 | WO2007051468A2 Preparation of an antibiotic crystalline fusidic acid |
| 05/10/2007 | WO2007051462A2 Use of tetraorganosilicon compounds |
| 05/10/2007 | WO2007051390A1 The use of eriocalyxin b in the manufacture of medicaments for treating leukemia |
| 05/10/2007 | WO2007051358A1 HYDROXYPROPYL-SULFOBUTYL-β-CYCLODEXTRIN, THE PREPARATION METHOD,THE ANALYTICAL METHOD AND THE PHARMACUTICAL APPLICATION THEREOF |
| 05/10/2007 | WO2007051333A1 Triazine beta-secretase inhibitors |
| 05/10/2007 | WO2007051316A1 Inhibition of autophagy genes in cancer chemotherapy |
| 05/10/2007 | WO2007051314A1 Curcuminoid compounds for inhibiting plasminogen activator inhibitor-1 |
| 05/10/2007 | WO2007051303A1 MODIFIED siRNA MOLECULES AND USES THEREOF |
| 05/10/2007 | WO2007033366A3 Biphenyl-pyrazolecarboxamide compounds |
| 05/10/2007 | WO2007033266A3 Dipeptidyl peptidase inhibitors for treating diabetis |
| 05/10/2007 | WO2007031291A3 Foodstuff additive |
| 05/10/2007 | WO2007030574A3 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds |
| 05/10/2007 | WO2007029642A9 Remedy for osteoporosis with the use of retinoid x receptor-related compound |
| 05/10/2007 | WO2007029029A3 Tetracyclic indole derivatives as antiviral agents |
| 05/10/2007 | WO2007027476A3 Treating premature ejaculation using gabapentin and pregabalin prodrugs |
| 05/10/2007 | WO2007026358A3 Compositons comprising phosphatidic acid for treatment of eosinophilia and related disorders |
| 05/10/2007 | WO2007025991A3 Treatment of optic neuritis |
| 05/10/2007 | WO2007025943A3 Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| 05/10/2007 | WO2007025897A3 Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives |
| 05/10/2007 | WO2007025286A3 Therapy procedure for drug delivery for trigeminal pain |
| 05/10/2007 | WO2007024612A3 8-substituted benzoazepines as toll-like receptor modulators |
| 05/10/2007 | WO2007023281A3 Biologically active compounds |
| 05/10/2007 | WO2007022934A3 Azabicyclo (3, 1, 0) hexan derivatives useful as modulators of dopamine d3 receptors |
| 05/10/2007 | WO2007022321A3 Substituted indoles and use thereof |
| 05/10/2007 | WO2007022113A3 Solid dosage forms of valsartan and amlodipine and method of making the same |
| 05/10/2007 | WO2007022102A3 Pentacyclic kinase inhibitors |
| 05/10/2007 | WO2007020286A3 Method of using potassium channel inhibiting compounds |
| 05/10/2007 | WO2007018432A3 Marrubiin and composition for reducing snoring, package and method |
| 05/10/2007 | WO2007017894A3 PREPARATION OF NOVEL CRYSTALLINE η(ETA) FORM OF PERINDOPRIL ERBUMINE |
| 05/10/2007 | WO2007017893A3 Preparation of novel crystalline form of perindopril erbumine monohydrate |
| 05/10/2007 | WO2007016108B1 Compositions for affecting weight loss |
| 05/10/2007 | WO2007015017A3 Novel polyquinoline derivatives and the therapeutic use thereof |
| 05/10/2007 | WO2007014895A3 Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives |
| 05/10/2007 | WO2007013950A3 Combination therapy of her expressing tumors |
| 05/10/2007 | WO2007010273A3 Use of thiazole derivatives and analogues in the treatment of cancer |
| 05/10/2007 | WO2007009637A3 Complexes containing perfluoroalkyl, their use as contrast media for nmr, x-ray and radio diagnosis and radiotherapy |
| 05/10/2007 | WO2007008539A3 Pyranopyridine compounds |
| 05/10/2007 | WO2007007282A3 Azabicyclo derivatives as muscarinic receptor antagonists |
| 05/10/2007 | WO2007007281A3 Muscarinic receptor antagonists |
| 05/10/2007 | WO2007007133A3 Composition for treatment of psychosis |
| 05/10/2007 | WO2007005672A3 Treatment and prevention of respiratory diseases and conditions |
| 05/10/2007 | WO2007005620A3 Arginase ii: a target treatment of aging heart and heart failure |
| 05/10/2007 | WO2007002701A3 Anti-inflammatory aryl nitrile compounds |
| 05/10/2007 | WO2007002667A3 Azaindazole compounds and methods of use |
| 05/10/2007 | WO2006138681A3 Methods and compositions for enhancing immune memory by blocking intrahepatic activated t cell deletion |
| 05/10/2007 | WO2006138428A3 Modulators of sperm hypermotility and uses thereof |
| 05/10/2007 | WO2006138373A3 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF |
| 05/10/2007 | WO2006135434A3 Semi-soft c-class immunostimulatory oligonucleotides |
| 05/10/2007 | WO2006134491A3 New crystalline form of moxifloxacin hydrochloride and process for its preparation |
| 05/10/2007 | WO2006133446A9 Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes |
| 05/10/2007 | WO2006133257A9 Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy |